Advanced

Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.

Haiman, Christopher A; Stram, Daniel O; Vickers, Andrew J; Wilkens, Lynne R; Braun, Katharina; Valtonen-André, Camilla LU ; Peltola, Mari; Pettersson, Kim; Waters, Kevin M and Marchand, Loic Le, et al. (2012) In Journal of the National Cancer Institute
Abstract
BackgroundA common genetic variant (rs10993994) in the 5' region of the gene encoding β-microseminoprotein (MSP) is associated with circulating levels of MSP and prostate cancer risk. Whether MSP levels are predictive of prostate cancer risk has not been evaluated.MethodsWe investigated the prospective relationship between circulating plasma levels of MSP and prostate cancer risk in a nested case-control study of 1503 case subjects and 1503 control subjects among black, Latino, Japanese, Native Hawaiian, and white men from the Multiethnic Cohort study. We also examined the ability of MSP to serve as a biomarker for discriminating prostate cancer case subjects from control subjects. All statistical tests are two-sided.ResultsIn all racial... (More)
BackgroundA common genetic variant (rs10993994) in the 5' region of the gene encoding β-microseminoprotein (MSP) is associated with circulating levels of MSP and prostate cancer risk. Whether MSP levels are predictive of prostate cancer risk has not been evaluated.MethodsWe investigated the prospective relationship between circulating plasma levels of MSP and prostate cancer risk in a nested case-control study of 1503 case subjects and 1503 control subjects among black, Latino, Japanese, Native Hawaiian, and white men from the Multiethnic Cohort study. We also examined the ability of MSP to serve as a biomarker for discriminating prostate cancer case subjects from control subjects. All statistical tests are two-sided.ResultsIn all racial and ethnic groups, men with lower MSP levels were at greater risk of developing prostate cancer (odds ratio = 1.02 per one unit decrease in MSP, P < .001 in the prostate-specific antigen [PSA]-adjusted analysis). Compared with men in the highest decile of MSP, the multivariable PSA-adjusted odds ratio was 3.64 (95% confidence interval = 2.41 to 5.49) for men in the lowest decile. The positive association with lower MSP levels was observed consistently across racial and ethnic populations, by disease stage and Gleason score, for men with both high and low levels of PSA and across all genotype classes of rs10993994. However, we did not detect strong evidence of MSP levels in improving prostate cancer prediction beyond that of PSA.ConclusionsRegardless of race and ethnicity or rs10993994 genotype, men with low blood levels of MSP have increased risk of prostate cancer. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of the National Cancer Institute
publisher
Oxford University Press
external identifiers
  • wos:000314865300010
  • pmid:23213189
  • scopus:84873593387
ISSN
1460-2105
DOI
10.1093/jnci/djs486
language
English
LU publication?
yes
id
880fb674-8edd-4f68-a2ea-eea584e8f321 (old id 3347608)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23213189?dopt=Abstract
date added to LUP
2013-01-02 12:19:38
date last changed
2017-05-21 03:55:25
@article{880fb674-8edd-4f68-a2ea-eea584e8f321,
  abstract     = {BackgroundA common genetic variant (rs10993994) in the 5' region of the gene encoding β-microseminoprotein (MSP) is associated with circulating levels of MSP and prostate cancer risk. Whether MSP levels are predictive of prostate cancer risk has not been evaluated.MethodsWe investigated the prospective relationship between circulating plasma levels of MSP and prostate cancer risk in a nested case-control study of 1503 case subjects and 1503 control subjects among black, Latino, Japanese, Native Hawaiian, and white men from the Multiethnic Cohort study. We also examined the ability of MSP to serve as a biomarker for discriminating prostate cancer case subjects from control subjects. All statistical tests are two-sided.ResultsIn all racial and ethnic groups, men with lower MSP levels were at greater risk of developing prostate cancer (odds ratio = 1.02 per one unit decrease in MSP, P &lt; .001 in the prostate-specific antigen [PSA]-adjusted analysis). Compared with men in the highest decile of MSP, the multivariable PSA-adjusted odds ratio was 3.64 (95% confidence interval = 2.41 to 5.49) for men in the lowest decile. The positive association with lower MSP levels was observed consistently across racial and ethnic populations, by disease stage and Gleason score, for men with both high and low levels of PSA and across all genotype classes of rs10993994. However, we did not detect strong evidence of MSP levels in improving prostate cancer prediction beyond that of PSA.ConclusionsRegardless of race and ethnicity or rs10993994 genotype, men with low blood levels of MSP have increased risk of prostate cancer.},
  author       = {Haiman, Christopher A and Stram, Daniel O and Vickers, Andrew J and Wilkens, Lynne R and Braun, Katharina and Valtonen-André, Camilla and Peltola, Mari and Pettersson, Kim and Waters, Kevin M and Marchand, Loic Le and Kolonel, Laurence N and Henderson, Brian E and Lilja, Hans},
  issn         = {1460-2105},
  language     = {eng},
  month        = {12},
  publisher    = {Oxford University Press},
  series       = {Journal of the National Cancer Institute},
  title        = {Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.},
  url          = {http://dx.doi.org/10.1093/jnci/djs486},
  year         = {2012},
}